# Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

> **NCT01364649** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 447 (actual)

## Conditions studied

- Treatment Outcome

## Interventions

- **DRUG:** Vortioxetine
- **DRUG:** Escitalopram
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01364649
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 447 (ACTUAL)
- **Last updated:** 2014-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01364649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01364649, "Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01364649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*